Quoin Pharmaceuticals
Manufacturing · Virginia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
42127 Pleasant Forest Ct, Ashburn, Virgi...Phone Number
(703) 980-4182Website
www.quoinpharma.comRevenue
$9.1 MillionStock Symbol
QNRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapeutic drug products that treat rare and orphan diseases. The company's mission is very simple; to bring hope where there is currently none. The company is totally committed to addressing critical, unmet medical needs for patients, their families, communities and care teams.Explore more
Quoin Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Quoin Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Quoin Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Quoin Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Quoin Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Quoin Pharmaceuticals is spiking on competitors!
Click to see if Quoin Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Quoin Pharmaceuticals has new funding data
Quoin Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Quoin Pharmaceuticals
Recommended Actions
Reach out to Masked Content who joined Quoin Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Quoin Pharmaceuticals
Compare insights from companies similar to Quoin Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Quoin Pharmaceuticals
$9.1M
1-10
Public
$209.8M
2021
DC
Denise CarterCo-Founder Quoin Pharmaceuticals Inc. and Chief Operating Officer
Company Profile Activity
Activity Insights
Quoin Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Quoin Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Quoin Pharmaceuticals.
Quoin Pharmaceuticals financials insights
Gather financial insights about Quoin Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$104.5M
Private Equity
$105.3M
Quoin Pharmaceuticals Tech Stack
A closer look at the technologies used by Quoin Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Quoin Pharmaceuticals News & Media
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Quoin advances its U.S. patent protection with allowed claims supporting QRX003's investigational approach to treating Netherton Syndrome.Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome.Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territoriesQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Quoin Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapeutic drug products that treat rare and orphan diseases. The company's mission is very simple; to bring hope where there is currently none. The company is totally committed to addressing critical,... Read More
